Boston Partners’s Ovid Therapeutics OVID Stock Holding History

Boston Partners’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-77,003	Closed	-$199K	–	732
2023 Q1	$199K	Hold	77,003	–	–	﹤0.01%	674
2022 Q4	$143K	Hold	77,003	–	–	﹤0.01%	678
2022 Q3	$142K	Buy	77,003 +847	+1%	+$1.77K	﹤0.01%	686
2022 Q2	$164K	Sell	76,156 -8,105	-10%	-$19.6K	﹤0.01%	676
2022 Q1	$265K	Hold	84,261	–	–	﹤0.01%	663
2021 Q4	$270K	Buy	+84,261	New	+$289K	﹤0.01%	650

Other funds holding OVID

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

TLS Advisors Miami, Florida $34M AUM 11.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Boston Partners's OVID Position: Q2 2023 in Review

Boston Partners sold out of Ovid Therapeutics (OVID) in Q2 2023, closing a stake of 77,003 shares — an estimated $199K sold.

Boston Partners first reported a position in OVID in Q4 2021 and held it in 6 quarters. The position peaked at $270K in Q4 2021. 69 funds tracked by Wall St. Rank hold OVID as of Q2 2023.

Boston Partners reported no remaining Ovid Therapeutics position as of Q2 2023 after selling out during the quarter.
Boston Partners sold 77,003 Ovid Therapeutics shares in Q2 2023, an estimated $199K.
Boston Partners first reported a position in Ovid Therapeutics in Q4 2021 and held it in 6 quarters.
Boston Partners's Ovid Therapeutics position peaked at $270K in Q4 2021.
69 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2023.

Based on Boston Partners's 13F filing for Q2 2023, filed 10 Aug 2023.